EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

Immunoreactivity of the 14F7 Mab (Raised against N-Glycolyl GM3 Ganglioside) as a Positive Prognostic Factor in Non-Small-Cell Lung Cancer

Rancés Blanco, Charles E Rengifo, Mercedes Cedeño, Milagros Frómeta, Enrique Rengifo, Adriana Carr

Pathology Research International · 2012

DOI: 10.1155/2012/235418 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathology Research International, 2012. Verfasst von Rancés Blanco und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Recognition and Biological Activity Assays, Department of Quality Control, Center of Molecular Immunology, Playa, P.O. Box 16040, Havan…. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0). Gefördert von: Center of Molecular Immunology.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung carcinoma is the leading cause of cancer-related mortality worldwide. Therefore, numerous studies are focusing on the assessment of other biological and molecular prognostic factors in these tumors. We evaluated the relationship between 14F7 Mab reactivity, pathological features, DNA-content and S-phase fraction (SPF), and their impact in the survival of NSCLC patients. Hematoxylin and eosin staining and immunohistochemistry optical microscopy assays as well as DNA content and SPF measuring using flow cytometry were performed. The 14F7 reactivity was widely observed in NSCLC sections, no depending of the clinicopathological characteristics. We also obtained differences in the intensity of reaction with 14F7 as well as in the SPF between diploid and aneuploid carcinomas. Patients with diploid tumors showing higher SPF and 14F7 reaction joint to a low mitotic index displayed higher survival rates. Our results are in agreement with the assumption of the possible positive prognostic value of 14F7 staining in NSCLC.

Autor:innen und Institutionen

  • Laboratory of Recognition and Biological Activity Assays, Department of Quality Control, Center of Molecular Immunology, Playa, P.O. Box 16040, Havana 11600, Cuba.

Förderung

  • Center of Molecular Immunology

Zitieren

APA

Blanco, R., Rengifo, C. E., Cedeño, M., Frómeta, M., Rengifo, E., & Carr, A. (2012). Immunoreactivity of the 14F7 Mab (Raised against N-Glycolyl GM3 Ganglioside) as a Positive Prognostic Factor in Non-Small-Cell Lung Cancer. Pathology Research International. https://doi.org/10.1155/2012/235418

Vancouver

Blanco R, Rengifo CE, Cedeño M, Frómeta M, Rengifo E, Carr A. Immunoreactivity of the 14F7 Mab (Raised against N-Glycolyl GM3 Ganglioside) as a Positive Prognostic Factor in Non-Small-Cell Lung Cancer. Pathology Research International. 2012. doi:10.1155/2012/235418

BibTeX
@article{Blanco2012,
  author = {Blanco, Rancés and Rengifo, Charles E and Cedeño, Mercedes and Frómeta, Milagros and Rengifo, Enrique and Carr, Adriana},
  title = {Immunoreactivity of the 14F7 Mab (Raised against N-Glycolyl GM3 Ganglioside) as a Positive Prognostic Factor in Non-Small-Cell Lung Cancer},
  journal = {Pathology Research International},
  year = {2012},
  doi = {10.1155/2012/235418}
}
Kostenlos starten →